---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-024375"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:27:08.315920+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC

## Summary
- CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.
- Phase 2 CRDF-004: onvansertib 30mg + FOLFIRI/bev showed 72.2% ORR vs 43.2% SoC (p=0.051) and PFS HR 0.37 vs SoC (p=0.048).
- Company selected 30mg dose of onvansertib with FOLFIRI/bev for registrational program; plans to initiate later in 2026 after FDA consultation.
- Final data and registrational plans expected in H1 2026; onvansertib well-tolerated with no additive toxicity.
- Conference call today at 8:30 a.m. ET to discuss results and strategy.

## SEC filing metadata
- accession: 0001193125-26-024375
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312526024375/0001193125-26-024375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312526024375/crdf-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-024375
- JSON: https://secwatch.observer/filing/0001193125-26-024375.json
- Plain text: https://secwatch.observer/filing/0001193125-26-024375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.